Solid Biosciences (SLDB) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.42
- EPS estimate
- −$0.50
- EPS surprise
- +16.70%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Solid Biosciences reported Q2 2025 results on August 12, 2025, the most recent quarter in the table. It posted a loss of $0.42 per share, narrower than the expected $0.50 loss, a beat of 16.70%. No revenue was reported. Compared with Q2 2024, the loss narrowed from $0.61 per share.
All 18 quarters shown were losses, and the loss per share has narrowed over time. The largest was $6.60 in Q3 2020, the oldest row, and Q2 2025 was the smallest. Full-year losses were $10.20 per share in 2021, $4.84 in 2023 and $3.04 in 2024; 2022 is incomplete in the table. The first half of 2025 lost $1.01 per share, against $1.25 a year earlier. Revenue appears only for 2021 and the first half of 2022, between $1.9 million and $6.2 million a quarter, with $13.6 million in 2021. Solid Biosciences beat the EPS estimate ten times in 18 quarters.
The table has no report after August 2025. In earlier years, Q3 results came out in early to mid-November and Q4 results in March. Once newer quarters are added, they will show whether the narrowing of the loss per share continued.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.50 | −$0.42 | +16.70% | $0.00 | SEC |
| Q1 2025 | May 15, 2025 | −$0.56 | −$0.59 | −6.27% | $0.00 | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.80 | −$1.00 | −24.24% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.67 | −$0.79 | −18.23% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.66 | −$0.61 | +8.08% | $0.00 | SEC |
| Q1 2024 | May 15, 2024 | −$0.64 | −$0.64 | −0.08% | $0.00 | SEC |
| Q4 2023 | Mar 13, 2024 | −$1.02 | −$1.00 | +2.04% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$1.18 | −$1.05 | +11.20% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$1.37 | −$1.25 | +8.78% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$1.61 | −$1.54 | +4.44% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$2.66 | −$2.71 | −1.74% | $0.00 | — |
| Q2 2022 | Aug 11, 2022 | −$3.25 | −$3.30 | −1.54% | $6.2M | SEC |
| Q1 2022 | Apr 27, 2022 | −$2.91 | −$3.30 | −13.31% | $1.9M | SEC |
| Q4 2021 | Mar 14, 2022 | −$3.00 | −$2.40 | +20.00% | $3.2M | — |
| Q3 2021 | Nov 3, 2021 | −$2.68 | −$2.40 | +10.40% | $3.5M | — |
| Q2 2021 | Aug 16, 2021 | −$2.61 | −$2.55 | +2.13% | $3.6M | SEC |
| Q1 2021 | May 14, 2021 | −$4.86 | −$2.85 | +41.36% | $3.3M | SEC |
| Q3 2020 | Nov 5, 2020 | −$5.52 | −$6.60 | −19.57% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Solid Biosciences (SLDB) last report earnings?
Solid Biosciences last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did SLDB beat earnings estimates?
Yes. Solid Biosciences reported EPS of −$0.42 for Q2 2025 against a −$0.50 estimate — a 16.70% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.